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Abstract
Background: This study aimed to estimate rates of chlamydia incidence and re-infection and to investigate the dynamics of
chlamydia organism load in prevalent, incident and re-infections among young Australian women.
Methods: 1,116 women aged 16 to 25 years were recruited from primary care clinics in Australia. Vaginal swabs were
collected at 3 to 6 month intervals for chlamydia testing. Chlamydia organism load was measured by quantitative PCR.
Results: There were 47 incident cases of chlamydia diagnosed and 1,056.34 person years of follow up with a rate of 4.4 per
100 person years (95% CI: 3.3, 5.9). Incident infection was associated with being aged 16 to 20 years [RR=3.7 (95%CI: 1.9,
7.1)], being employed [RR=2.4 (95%CI: 1.1, 4.9)] and having two or more new sex partners [RR=5.5 (95%CI: 2.6, 11.7)].
Recent antibiotic use was associated with a reduced incidence [RR:0.1 (95%CI: 0.0, 0.5)]. There were 14 re-infections with
a rate of 22.3 per 100 person years (95%CI: 13.2, 37.6). The median time to re-infection was 4.6 months. Organism load was
higher for prevalent than incident infections (p,0.01) and for prevalent than re-infections (p,0.01).
Conclusions: Chlamydia is common among young women and a high proportion of women are re-infected within a short
period of time, highlighting the need for effective partner treatment and repeat testing. The difference in organism load
between prevalent and incident infections suggests prevalent infection may be more important for ongoing transmission of
chlamydia.
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Introduction
Chlamydia trachomatis (chlamydia) is the most common bacterial
sexually transmitted infection (STI) worldwide. Both men and
women can be infected with chlamydia causing urethritis and
epididymitis in men and cervicitis in women [1,2,3]. If left
untreated, chlamydia can lead to pelvic inflammatory disease
(PID), tubal factor infertility and ectopic pregnancy in women
[2,4].
Chlamydia incidence estimates among women vary according
to the population studied and range from between 4.9% per year
in general practice populations in the UK [5] and 34 per 100
person-years in high-risk adolescents in the US [6]. Re-infection
estimates also vary, but have been found to range between 4 to
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e3777851% per year [7,8,9,10] in community-based studies and up to
84% in high-risk adolescents [6].
There are inconsistent findings about clinical and epidemiolog-
ical associations with organism load. Some research reports
associations between increased organism load and younger age
[11], transmissibility and persistence of infection [12] and the risk
of developing chronic sequelae [13], with more recent research
finding no such associations [14,15]. However, most studies have
investigated organism load using a cross-sectional study design
where it is not possible to determine when the infection was
acquired [11,13,15,16]. This highlights the need for longitudinal
studies of chlamydial load in incident infection to further our
understanding of whether organism load may be associated with
chlamydia transmission.
We describe here the results of a cohort study of young women
that aimed to estimate rates of chlamydia incidence and re-
infection and to investigate the dynamics of chlamydia organism
load in prevalent, incident and re-infection.
Methods
Recruitment
Women aged 16 to 25 years were recruited from general
practice, family planning and sexual health clinics in Victoria,
New South Wales and the Australian Capital Territory, three
jurisdictions in South-Eastern Australia. The methods have been
previously described [17]. In brief, written informed consent was
obtained by all participants in the study. All eligible women were
assessed for competency by research staff prior to being invited
into the study. The research staff worked closely with the clinical
staff to ensure only competent women were approached. All ethics
committees approved the inclusion of participants over the age of
16 without parental or guardian consent. Women were recruited
when they attended the clinic for any reason during the
recruitment period and were eligible if they had ever had vaginal
sex with a man, were not pregnant, could comprehend written
English and were contactable by post during the 12-month period
of the study. Women were tested at the time of recruitment
(baseline) and at 6 and 12 months; women who tested positive at
any stage were also re-tested three months after a positive test. All
follow-up testing was conducted using self-collected vaginal swabs
sent through the mail.
Testing, organism load and serovar determination
Chlamydia testing. At the time of recruitment, women
provided a first-pass urine specimen or self-collected vaginal swab
which was tested by their clinician’s pathology provider using
nucleic acid amplification techniques (NAAT). They also provided
an additional self collected flocked swab (Copan, Brescia, Italy) at
baseline which was sent to the Molecular Microbiology Labora-
tory at the Department of Microbiology and Infectious Diseases, at
the Royal Women’s Hospital, Melbourne, Australia for quantifi-
cation of chlamydial load and serovar determination should the
woman be diagnosed with chlamydia at baseline. At each point in
follow up, women were tested using a self-collected flocked swab
that was sent through the Australian postal system to the
laboratory at the Royal Women’s Hospital. Chlamydia testing
was performed using the Cobas TaqMan CT assay (Roche
Applied Science) as per the manufacturer’s instructions with 25 ml
of extracted DNA using amplification and detection on the Cobas
TaqMan 48 System (Roche Applied Science).
Quantification of organism load. Once detected, quanti-
fication of chlamydial load was determined by a quantitative PCR
(qPCR) system targeting the omp1 gene using published method-
ology [18]. The chlamydia load in each sample was quantified by
comparing the crossing-threshold of each sample to the crossing-
threshold of a standard curve constructed by amplifying different
known copy numbers of the omp1 gene. This method also
determined whether any mixed infections were present, and
identified the chlamydia serovar(s) of each infection through
a series of qPCR assays using serovar-specific probes. Beta globin
gene qPCR was used to assess sample adequacy as well as to
measure sampling variability between participants and swabs by
correlation with the number of eukaryotic cells collected. The
quantity of chlamydia was divided by the number of eukaryotic
cells and expressed as the number of organisms present per 100
eukaryotic cells [14].
Serovar detection. Confirmation of each chlamydia serovar,
and detection of genotypic variants was determined by DNA
sequencing across all four variable domains of the omp1 gene that
encodes for the antigenic major outer membrane protein as
previously described [19].
Management of participants
Women who tested positive at baseline were managed by their
clinician. The research team provided free treatment of 1 gram
stat of oral azithromycin. Clinicians were given an education pack
with the latest treatment guidelines [20], partner notification
support and a telephone number they could call to discuss clinical
management of STIs with a sexual health physician [17]. The
research team contacted each clinic after recruitment to confirm
that the azithromycin was prescribed to women testing positive for
chlamydia at baseline. If a participant tested positive during the
course of the study, she was contacted by the research team who
coordinated a telephone consultation with a sexual health
physician. Azithromycin was sent to the participant free of charge
along with partner notification letters and information sheets
about chlamydia. When appropriate, treatment was provided to
the woman’s current sex partner. If the sexual health physician
decided more clinical intervention was required, arrangements
were made so that the woman had a face-to-face consultation with
a clinician.
Definitions
A prevalent infection was defined as a positive chlamydia result at
the time of recruitment (baseline). An incident infection was defined
as a positive chlamydia result diagnosed on a follow up test during
the study period. Women were classified as having a re-infection if
they tested positive for chlamydia again during follow up after
a previous positive result earlier in the study, with or without
a negative test in between positive test results. The subsequent
positive results were defined as re-infections. Any re-infections
diagnosed were also considered incident infections. To differen-
tiate between chlamydia re-infection, treatment failure or persistent infection,
we used a modified version of the chlamydia re-infection algorithm
developed by Batteiger and colleagues (Figure 1) [6]. If a woman
had two infections with different genotypes, then the second
infection was considered a re-infection. If there had been
a confirmed negative test between two positive results, the second
infection was also considered a re-infection. If women had taken
the correct antibiotics but had unprotected sex with her current
partners or new partners, the second infection was also considered
a re-infection. Treatment failure was defined as a positive chlamydia
result following treatment with azithromycin if a woman reported
she had either abstained from sex between the two tests or always
used condoms with sex. An infection was defined as persistent if the
woman had two consecutive positive chlamydia test results and
was not treated following the first positive result.
The Influence of Chlamydia Organism Load
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At recruitment, women were asked to complete a self-admin-
istered paper-based questionnaire which collected demographic
data. Paper-based questionnaires were also sent every three
months and asked about sexual behaviour (number of sex partners,
new sex partners and condom use), recent antibiotic and
contraceptive use, and any pregnancies including termination
and/or miscarriages. It also included questions about the presence
of any recent genital symptoms, including abnormal vaginal
discharge, abnormal vaginal odour, dysuria, abdominal pain and
abnormal vaginal bleeding.
Statistical methods
Calculations assuming a design effect of 2 indicated that
a sample size of 1,000 would be sufficient to generate a 95%
confidence interval incidence of 2.8 to 6.2 events per 100 person-
years if the estimated rate is 4.5 events per 1000 person-years.
Chlamydia incidence and re-infection rates and 95% confidence
intervals (95% CIs) based on the estimation of robust standard
errors were calculated using Poisson regression. The rate of re-
infection was calculated using only data from those who tested
positive at least once during the study and had two or more tests.
The Kaplan-Meier method was used to estimate the cumulative
risk over time (equivalently the probability of remaining infection-
free to any given time) of incident chlamydia infection or re-
infection after initial infection. Follow-up was censored at 18
months after enrolment. The association between demographic,
behavioural and clinical factors and the chlamydia incident or re-
infection was investigated using a discrete-time version of the
proportional-hazards regression model described by Carlin et al
[21] from which rate ratios and robust standard errors were
generated. For the purpose of the Kaplan Meier and proportional
hazards regression modeling, re-infections were also considered as
incident infections and included in the analysis of incident
infections.
Factors associated with infection risk in a univariate analysis or
that were clinically important in the view of the investigators were
included in the multivariate model; if two factors were highly
correlated, only one was included in the model.
The chlamydia organism load values were logarithm trans-
formed for the purpose of analysis. Box plots were used to display
the interquartile range, median value and overall range of
organism load values. For the purpose of the box plots, data were
stratified by infection type – prevalent, incident (where re-
infections are excluded) and re-infection. T-tests or Mann-
Whitney U-tests were used to compare organism load between
groups where appropriate. Data were analysed using STATA
version 11.1 [22].
Ethics approval to conduct this study was obtained from ten
Human Research Ethics Committees throughout Australia.
Results
Sample characteristics
A total of 1116 women participated in the study with
a recruitment response rate of 66%. The retention in the study
over the 12 month period was 79% (877 women). There were
2,937 chlamydia tests conducted throughout the study. Overall,
738 women (66%) were recruited from general practice clinics and
378 (34%) were recruited from sexual health and family planning
clinics. There were 55 cases of chlamydia diagnosed at the time of
recruitment with a chlamydia prevalence of 4.9% (95% CI: 3.7%,
6.4%).
Figure 1. Algorithm to differentiate between chlamydia re-infection, treatment failure and persistent infection [adapted from
Batteiger et al (2009)] [6]. N/A=Serovar result not available.
doi:10.1371/journal.pone.0037778.g001
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During the follow-up period, there were 47 cases classified as
incident infections and 1056.34 person years of follow up with an
incidence rate of 4.4 per 100 person-years (95% CI: 3.3, 5.9). Six
women were diagnosed with two separate incident infections
during the study period and 35 with a single incident infection.
Chlamydia incidence was greatest 6 to 9 months after recruitment
with 25 incident cases diagnosed during this time [rate=9.2 per
100 person-years (95%CI: 6.2, 13.7)] (Figure 2). Chlamydia
incidence was similar between women recruited from general
practice clinics and those recruited from sexual health or family
planning clinics [4.6 (95%CI: 3.3, 6.5) versus 4.1 (95%CI: 2.4, 7.0)
per 100 person-years (p=0.68)].
Univariate analysis found that being aged 16 to 20 years
[RR=3.5 (95%CI: 1.8, 6.8)], being less well educated [RR=3.0
(95%CI: 1.4, 6.5)] and having two or more new sex partners
[RR:4.8 (95%CI:2.4, 9.8)] were associated with incident chla-
mydia. Recent antibiotic use [RR:0.1 (95%CI: 0.0, 0.6)] was
associated with reduced incidence. Multivariate analysis found
that being aged 16 to 20 years [RR=3.7 (95%CI: 1.9, 7.1)], being
employed [RR=2.4 (95%CI: 1.1, 4.9)] and having two or more
new sex partners [RR=5.5 (95%CI: 2.6, 11.7)] were associated
with an increased incidence of chlamydia. Recent antibiotic use
[RR:0.1 (95%CI: 0.0, 0.5)] was associated with a reduced
incidence. Education level was highly correlated with age
(p,0.01) and excluded from the model. Use of condoms,
previously having chlamydia, and other demographic character-
istics were not associated with incident infection (Table 1).
Re-infection
There were 81 women who were at risk of re-infection during
the study and contributed 62.7 years of follow-up. There were 14
re-infections of which seven were considered ‘definite’ re-infections
in women who had had either a negative test in between two
positive tests (four cases) or different serovars for each test (three
cases). The other seven were ‘probable’ re-infections in women
who had had unprotected sex in between positive results. Three
women had two episodes of re-infection and eight had one episode
of repeat infection. The overall re-infection rate was 22.3 (95%CI:
13.2, 37.6) per 100 person-years and the cumulative risk of re-
infection during the study period was 20.3% (95%CI: 11.6, 31.7).
The median time to re-infection was 4.6 months with 50% of re-
infections acquired between 3.5 and 6.6 months after initial
infection (Figure 3).
There were no associations found between re-infection and
participant characteristics (Table 1).
Persistent infections, treatment failure and ‘false
positives’
One persistent infection was diagnosed in a woman who failed
to take the prescribed antibiotics between two positive results of
the same serovar. One possible case of treatment failure was
identified in a woman who stated she had always had protective
sex with condoms and her partner had been treated concurrently.
One false positive was found in a participant who tested positive at
follow-up despite taking antibiotics and having no risk of re-
exposure. This woman was sent another swab that tested negative,
and we concluded from her low risk of re-infection that her first
test had been a false positive result. She was prescribed
azithromycin as a precaution.
Organism load by infection type
Organism load was able to be measured for 50 (91%) prevalent
infections, 24 (73%) incident (excluding re-infections) infections
and 11 (79%) re-infections. Organism load was significantly higher
for the 50 prevalent infections than for the 24 incident infections
(excluding re-infections) (p,0.01) or the 11 re-infections (p,0.01).
Organism load was not different between the 11 re-infections and
the 24 incident infections (excluding re-infections) (p=0.33)
(Figure 4).
Organism load for re-infections
For those with a re-infection, organism load was significantly
lower for the first repeat infection compared with the initial
infection (p,0.01), but there was no difference in load between the
first and second repeat infections (p=0.49) (Table 2).
There were 63 women who tested positive during the study, had
a follow up test and had organism load measured. This includes 37
women whose first positive result was detected at baseline and 26
women whose first positive result was detected on a follow up test.
Among these 63 women, four (6%) were diagnosed with a repeat
infection of the same serovar at their next test; the other 59 women
tested negative (57) or tested positive with a different serovar
(2).The organism load at the first test was higher for the four
women who tested positive again with the same serovar than for
those women who tested negative at their next test, although this
was not a statistically significant difference (p=0.06) (Figure 5).
Organism load was not associated with age (data not shown).
Serovars
The chlamydia serovar was detected in the 39 of the 47 positive
incident chlamydia samples; 60% were serovar E (n=28), 11%
were serovar F (n=5), 6% were serovar D (n=3), 4% were
serovar G (n=2) and 2% were serovar H (n=1). The chlamydia
serovars detected in the re-infection samples were primarily
serovar E (n=12, 86%), one was serovar D (7%) and one was
serovar F (7%). Among prevalent infections, the majority were
serovar E (Table 3). Overall, there were no associations observed
between serovar and organism load or serovars and demographic
characteristics.
Discussion
We present the incidence and re-infection rate data for a large
cohort of young women and provide the first published
quantitative data that investigates chlamydia organism load and
Figure 2. Kaplan Meier curve showing proportion remaining
uninfected with incident chlamydia infection over time among
a cohort of sexually active 16 to 25 year old women.
doi:10.1371/journal.pone.0037778.g002
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infections. We found very high re-infection rates of 22.3 per 100
person years and also found that organism load was higher in
prevalent infections than in incident infections. These findings
indicate prevalent infections maybe more important to ongoing
transmission because of their higher organism load and chlamydia
control strategies should include a focus on reducing both
chlamydia prevalent infection and re-infection.
These data are the first chlamydia incidence and re-infection
data for Australian women and show a chlamydia incidence of 4.4
per 100 person-years and a re-infection rate of 22.3 per 100
person-years which is comparable to other research findings in the
UK [5]. We found that younger women (16 to 20 years old) and
women who had had more sex partners during the study period
were more likely to have an incident infection; this is also
consistent with other studies [5,23,24]. Interestingly, we found that
recent use of antibiotics was protective against an incident
infection; this was also observed in a recently conducted survey
of antenatal women in Australia [25] and raises the possibility that
background antibiotic use in a population may have an impact on
chlamydia transmission, particularly in Australia [26].
Table 1. Demographic and behavioural factors associated with chlamydia incident and re-infection among a cohort of sexually
active 16 to 25 year old women.
Incident infection* Re-infection
Variable
Incidence
per 100
person
years
Unadjusted rate
ratio (95% CI
a)
Adjusted rate
ratio
b (95% CIa)
Re-infection
rate per
100 person
years
Unadjusted rate
ratio (95% CI
a)
Adjusted rate
ratio
c (95% CIa)
Age
16 to 20 7.7 3.5 (1.8, 6.8) 3.7 (1.9, 7.1) 31.3 3.0 (0.8, 10.5) 3.1 (0.9, 11.5)
21 to 25 (referent) 2.1 1.0 1.0 10.8 1.0 1.0
Australian born
No (referent) 0.9 1.0 0.0 N/A N/A
Yes 5.1 5.6 (0.8, 40.1) 23.6
Area of residence
Rural (referent) 4.4 1.0 15.2 1.0 1.0
Metropolitan 4.5 1.1 (0.6, 2.0) 30.2 2.0 (0.6, 6.9) 2.2 (0.6, 7.7)
Education
Secondary school only 6.5 3.0 (1.4, 6.5) 23.9 1.2 (0.4, 3.7) 1.2 (0.4, 4.2)
Tertiary/further education (referent) 2.1 1.0 20.3 1.0 1.0
Employment
Unemployed/Not working(referent) 3.3 1.0 1.0 12.7 1.0 1.0
Employed 5.3 1.6 (0.8, 3.3) 2.4 (1.1, 4.9) 29.0 2.3 (0.5, 10.8) 2.3 (0.5, 10.6)
Clinic type
Sexual health/family planning clinic (referent) 4.1 1.0 1.0 28.1 1.0 N/A
General practice 4.6 1.1 (0.5, 2.3) 1.7(0.8, 3.8) 17.5 0.6 (0.2, 2.0)
Number of new partners since last follow up
0 (referent) 2.4 1.0 1.0 32.1 1.0 1.0
1 8.1 3.2 (1.6, 6.8) 3.1 (1.5, 6.7) 6.7 0.2 (0.1, 1.6) 0.2 (0.1, 1.7)
2+ 14.3 4.8 (2.4, 9.8) 5.5 (2.6, 11.7) 14.8 0.5 (0.1, 1.9) 0.5 (0.1, 2.1)
Recently had antibiotics
No (referent) 5.4 1.0 1.0 23.5 1.0 1.0
Yes 0,5 0.1 (0.0, 0.6) 0.1 (0.0, 0.5) 15.3 0.6 (0.1, 4.4) 0.7 (0.1, 4.4)
Use of condoms
No (referent) 3.7 1.0 21.8 1.0 1.0
Yes 5.5 1.6 (0.9, 3.0) 24.2 1.1 (0.3, 3.7) 1.2 (0.3, 4.2)
Previous positive C. trachomatis
d
No (referent) 4.4 1.0
Yes 4.4 1.0 (0.3, 3.0)
*Analysis of incident infections includes re-infection.
a=confidence interval;
b=adjusted for age, employment, clinic type, number of new partners and recent antibiotic use;
c=adjusted for clinic type;
d=previous positive chlamydia test reported on questionnaire or diagnosed at time of recruitment into the study.
doi:10.1371/journal.pone.0037778.t001
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particularly considering the evidence suggesting that repeated
infections markedly increase a woman’s risk of PID and tubal
damage [27,28,29,30]. Australia is not alone with high re-infection
rates, similarly high rates have been observed in the UK among
women recruited from general practice and sexual health clinics
[5] and in the USA among high risk adolescents [6]. We found
that the median time until re-infection was 4.6 months. This
provides further support for a test of re-infection at about 3 months
which is currently recommended in Australia [20]. The high re-
infection rates also highlight the importance of partner notifica-
tion. Mathematical modelling of chlamydia transmission suggests
that about 30% of current sex partners need to be treated in order
to counterbalance the effect of re-infection [31]. Chlamydia
control policy must include a focus on reducing re-infection
through both increased re-testing at 3 months and improved
partner notification. A recent systematic review found that mailed
screening kits and reminder systems can be effective at increasing
re-testing [32] both of which would be feasible in general practice
with appropriate training and support.
The higher organism load in prevalent compared with incident
infections including re-infections, is difficult to interpret because
infections diagnosed at recruitment would have included both
recently acquired and infections of over 12 months duration.
However, it gives rise to a number of different hypotheses that may
help explain this difference in organism load. Firstly, organism
load may be lower with re-infections because past chlamydial
infection confers some protective immunity and impacts on
Figure 3. Kaplan Meier curve showing proportion remaining
free from chlamydia re-infection over time among a cohort of
sexually active 16 to 25 year old women.
doi:10.1371/journal.pone.0037778.g003
Figure 4. Comparison of chlamydia organism load for prevalent versus incident (excluding re-infection) and re-infection among
a cohort of sexually active 16 to 25 year old women [shaded box=interquartile range; black line in box=median value; T
bars=range of values].
doi:10.1371/journal.pone.0037778.g004
Table 2. Organism load per 100 cells during episodes of
chlamydia re-infection* among a cohort of sexually active 16
to 25 year old women.
Patient
ID
a Initial infection
1
st re-
infection
2
nd re-
infection Serovar
1 558.9 33.4 E, F
2 49886.9 48.9 E,E
3 43.7 17.7 E,E
4 2156.7 1.2 E,E
5 13110.5 ,0.01 22.4 E,E,E
6 3207.5 0.1 K,E
7 153.9 6.2 6.6 K,E,E
8 3706.9 0.4 F,E
9 789.5 372.7 E,E
*The time interval between the diagnoses was 3 to 6 months.
a=Excludes 2 people with missing organism load results.
doi:10.1371/journal.pone.0037778.t002
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chlamydial entry [14,33]. This protective immunity hypothesis
correlates well with the characteristics and mechanisms of partial
protection defined in mouse and guinea pig models of genital
infection [33]. However, proof of this hypothesis would require
further longitudinal studies that include collection of comprehen-
sive behavioural data to capture the duration of infection at
recruitment, baseline and subsequent sampling of immunological
markers together with serial sampling for incident infection and
determination of organism load [34]. A second hypothesis is that
organism load increases over time following infection. However,
this hypothesis seems unlikely because chlamydia infection will
naturally clear over time without treatment [35]. Further, mouse
models have shown that chlamydial shedding decreases over time
following infection [36,37]. A third hypothesis is that lower
organism load infections naturally clear more quickly than higher
load infections and on this basis, prevalent infections represent
a biased sample of higher organism load infections. This
hypothesis is supported by mathematical models of chlamydia
transmission.[38] Regardless of the mechanisms to explain the
Figure 5. Comparison of chlamydia organism load at first diagnosis between women who had a negative repeat rest and women
who had a positive repeat test of the same serovar among a cohort of sexually active 16 to 25 year old women [shaded
box=interquartile range; black line in box=median value; T bars=range of values].
doi:10.1371/journal.pone.0037778.g005
Table 3. Chlamydia trachomatis serovars and genotypic variants detected in positive samples among a cohort of sexually active
16 to 25 year old women.
Chlamydia serovar Genbank accession number Prevalent infection N (%)
Incident infection (including re-
infection) N (%)
Re-infection
N (%)
D HM230054 2 (3.6) 3 (6.4) 1 (7.1)
E HM230055 27 (49.1) 28 (59.6) 12 (85.7)
E variant
a HM230056 1 (1.8)
F HM230057 12 (21.8) 5 (10.6) 1 (7.1)
G HM230058 3 (5.5) 2 (4.3)
G variant
b HM230059 2 (3.6)
H HM230060 1 (2.1)
Ia HM230061 1 (1.8)
J HM230062 1 (1.8)
K HM230063 3 (5.5)
N/A
c 3 (5.5) 8 (17.0)
TOTAL 55 47 14
a=E variant has 100% homology to Genbank sequence GU903922 (C. trachomatis strain 1969 from Australian male population);
b=G variant has 100% homology to Genbank sequence FJ261928 (G/IU-FW0267);
c=N/A: serovar unable to be determined.
doi:10.1371/journal.pone.0037778.t003
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infections of shorter infection duration with quantitatively less
organism shedding are associated with decreased risk of trans-
mission which suggests prevalent infections maybe more important
to ongoing infection transmission. This highlights the importance
of increasing screening coverage among the target population in
chlamydia control programs. One other study has suggested that
organism load decreases with subsequent infections, but this was
based on only four participants [14], with our results providing
further evidence for this finding.
Also, we found that women with higher organism loads were
more likely to have a repeat infection of the same serovar at next
test than women who did not have a repeat infection at their next
test. While this was not a statistically significant result and based
on only four cases, a p value of 0.06 does provide some weak
evidence to warrant further discussion. It has been shown in
trachoma treatment studies that azithromycin failure is more likely
at higher organism loads and this raises the question of whether
some repeat infections in our study could represent treatment
failure rather than re-infection. Using our re-infection algorithm,
we did identify one potential case of treatment failure (2%) which
is lower than the 8% reported in similar studies. However, given
the time interval between tests in our study (three to six months on
average) it is likely that it was challenging for women to reliably
report sexual exposure between tests reducing our ability to
reliably differentiate between re-infection and treatment failure. In
light of the increasing concern about the possibility of azithromy-
cin treatment failure [6,39,40,41,42], further studies with larger
sample sizes and more frequent sampling are necessary to explore
this.
There were some limitations to our results. Firstly, our
algorithm and classification of re-infection is partially dependent
on self-reported sexual behaviour which can be influenced by
social desirability bias. Increasingly specific molecular analysis
such as the use of multi locus sequence typing (MLST) should help
reduce this bias, although it will not eliminate it [43]. Secondly,
the precision of our estimates of incident and re-infection rates and
cumulative risk reflect the availability of event data, which was
constrained by the frequency and timing of our specimen
collection. Our analysis of re-infection and organism load was
also limited by sample size. Thirdly, there are potential limitations
with the organism load analysis as a result of not being able to
analyse organism load on all the swabs. A greater proportion of
incident infections had missing organism load data than prevalent
infections. This is likely to be because of the reduced sensitivity of
qPCR when the organism load is low [18]. However, there were
no differences in participant characteristics including age or
number of partners between those who had measurable organism
load and those who did not. Variation in organism load may occur
daily as the infection progresses or resolves and may also be
affected by the state of the menstrual cycle [44]. However, it would
not be possible to control for the menstrual cycle due to hormonal
fluctuations that vary from one woman to another even at the
same stage of the cycle, which is difficult to measure precisely [14].
To adjust for individual sampling variability, organism load was
quantified relative to the number of eukaryotic cells per sample.
A recruitment response rate of 66% is very high for this type of
study exploring socially sensitive material [45]. However, as we
have described elsewhere, women who participated in this study
were more likely to be Australian born, more well educated and
reported a greater number of sex partners than the background
Australian population of the same age [17,46]. As a result, our
study may not be representative of all Australian 16 to 25 year old
women. Nevertheless, our retention rate of 79% over the duration
of the study with negligible loss to follow up bias is a significant
strength of our study, adding weight to our findings [17]. Further,
the serovars detected in the cohort were consistent with previously
published Australian and international data suggesting our results
were broadly representative of the Australian population.
This is the first published cohort study of chlamydia incidence
and re-infection among young women that has investigated
organism load by infection type. We have shown that chlamydia
is a common infection in young Australian women and
considering the high proportion of women who are re-infected
within a short period of time, innovative and effective strategies
are needed to encourage increased re-testing following a positive
diagnosis and improved partner notification. We also found that
organism load in incident infection is less than prevalent infections
suggesting that prevalent infection might be more important in the
transmission of chlamydia. Further longitudinal studies that use
serial collection of behavioral and biological data are necessary to
investigate protective immunity and the responsible mechanisms.
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